about
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance ProgramAlbumin reduces blood-brain barrier permeability but does not alter infarct size in a rat model of neonatal stroke.Penetration of naproxen and salicylate into inflammatory exudates in the rat.VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body.Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites.The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation.Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phasesDiazepam kinetics in patients with renal insufficiency or hyperthyroidism.The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2DPrazosin protein binding in health and disease.Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesisTransport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug.Serum albumin concentrations: who needs them?Interaction of warfarin with drugs, natural substances, and foods.Interaction of human serum albumin with anticancer agents in vitro.P-aminosalicylate metabolism in cancer patients sensitive and resistant to chemotherapy.Molecular analysis of the putative inactivation particle in the inactivation gate of brain type IIA Na+ channels.Interactive association of drugs binding to human serum albumin.Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin Resistant Staphylococcus aureus.Protein based therapeutic delivery agents: Contemporary developments and challenges.Differential effect of clofibrate on inflammation-induced alterations in plasma proteins in the rat.Protein binding and kinetics of drugs in liver diseases.Aspects of anticoagulant action: a review of the pharmacology, metabolism and toxicology of warfarin and congeners.The metabolism and biopharmaceutics of spironolactone in man.Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.Prostaglandin production by macrophages and the effect of anti-inflammatory drugs.Investigation on the Interaction of Hydroxyethyl Starch 130/0.4 (Voluven) and Serum Albumin for Pharmacokinetic and Toxicological Implications.Plasma and tissue binding considerations in drug disposition.Is volume of distribution at steady state a meaningful kinetic variable?Evaluation of three newer methods for investigating protein interactions of penicillin G.Binding of dipyridamole to human platelets and to alpha1 acid glycoprotein and its significance for the inhibition of adenosine uptake.Plasma protein binding displacement interactions--why are they still regarded as clinically important?Plasma protein binding of valproic acid in healthy subjects and in patients with renal diseaseMeasurement of 'free' gold in patients receiving disodium aurothiomalate and the association of high free to total gold levels with toxicity.Dose-dependency of theophylline clearance and protein binding.Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.Role of concentration-dependent plasma protein binding in disopyramide disposition.The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
P2860
Q24547894-F53FB989-08D0-4186-B3E2-B5AF86904BE8Q31118233-C71FA731-EE61-433D-B510-B441BE94656FQ33570008-27F78FAA-3FAC-45B2-AF86-E0A533C5EA73Q33674437-ED93D375-7BDB-4E70-B5B5-A99005F05CCAQ33896841-304F91C1-ECD0-439A-9730-2631D69ECA85Q34398214-1E9F1CF8-3203-4F41-ABED-2104FF2FCE5FQ34398308-2796A46A-000E-4C48-A970-159E776A445AQ34416228-5C513F89-591C-40E1-90DB-816FC56D8117Q34420976-97CECB11-400C-401D-BEE2-F92CC196FBFBQ34449546-7B1C1388-1EC9-45C5-91B5-99E62023192EQ34467682-EC00E18C-6E16-4783-A339-B785D42DB33EQ34518336-A2A3EEE8-AB50-41BD-8974-28601C95DB0CQ34613252-54F36908-F0CD-49D0-9441-F0E1E7459EA6Q35205603-F118DE9E-FBCE-4E03-8791-1B61F73EBEFFQ35466732-C3A20947-C59D-4CB5-96A6-2117D280C9BCQ36007599-6011DB7F-433D-4ED1-BAAB-4EBC1279CCF5Q36043868-86061A7F-CCE2-4987-909C-6C9385F34DD2Q36069321-D9D6B27F-58E7-4FDE-A5D2-9CD3837846C8Q36411866-86ECA837-A218-4FE7-83C9-99DCE4116EE5Q38192435-B804291F-DF3C-4B7C-97FF-C4AFCAC60F8FQ38310341-8B6DD856-21D3-4B2F-86A3-6B8C0D052EADQ39273739-9CF9D402-8325-4626-866B-09C950BB6A8FQ39552975-F720765E-E4B2-4A09-AD4A-4BDD8D0ABD82Q39620831-FAC83799-81F5-43C6-A592-61D14600E33BQ39705808-63D535FD-1229-40CB-93FE-EFD531667BFBQ39705813-9272027F-BAA5-4E6E-8991-44005AD051BFQ39783255-68D9D8EB-EC15-47A7-8DBD-012E85E5B2BCQ40045065-0515B679-C95A-442E-8B14-E6EA1281160AQ40125393-CFB6057A-2D4B-476F-9F6D-82474B75ABCDQ40153516-29E05D52-B0F2-442C-B345-E853D542D693Q40160720-EFF6E227-11BD-4E85-BF31-411AE6119DC9Q40617526-1B90569C-15FA-4EFF-B195-7422CC9B036BQ40691423-67377238-EDF1-41D2-8F1E-31823978BCF9Q40753816-88886102-3A7C-4818-B778-C53FB86D8A5CQ40897047-C9B47442-F0E2-4C85-A0B2-FDDBA8E04DFAQ41199267-C4519A73-4DEA-4D40-A8D8-4ABBF48C9D73Q41200686-674DD8E4-8723-4563-9B21-8A74CCDBC43BQ41651472-E2018A45-005C-4369-AF53-CE2A56706028Q41690921-8C8EA295-577A-4CE7-8139-0A501F90520CQ41876641-53138304-3521-4E7D-A74D-87C3C47EFF8A
P2860
description
1976 nî lūn-bûn
@nan
1976 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
Binding of drugs to serum albumin (first of two parts).
@ast
Binding of drugs to serum albumin (first of two parts).
@en
Binding of drugs to serum albumin
@nl
type
label
Binding of drugs to serum albumin (first of two parts).
@ast
Binding of drugs to serum albumin (first of two parts).
@en
Binding of drugs to serum albumin
@nl
prefLabel
Binding of drugs to serum albumin (first of two parts).
@ast
Binding of drugs to serum albumin (first of two parts).
@en
Binding of drugs to serum albumin
@nl
P1476
Binding of drugs to serum albumin (first of two parts).
@en
P2093
Koch-Weser J
Sellers EM
P304
P356
10.1056/NEJM197602052940605
P407
P577
1976-02-01T00:00:00Z